Seagen is on a roll this week. After naming David Epstein as its new CEO, the Washington-based biotech announced that Adcetris (brentuximab vedotin) has been given FDA approval for the treatment of children aged two years and above with high-risk classical Hodgkin lymphoma.
The regulatory nod, based on data from the Phase III study AHOD1331, covers the use of Adcetris with the chemotherapeutic agents doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
In a statement, Marjorie Green, MD, senior vice president and head of late-stage development at Seagen, said Adcetris has already been proven as a “groundbreaking medicine” for certain types of lymphomas in adults, and Thursday’s green light “extends its availability to younger patients.”